Roche Stock News

Basel, 06 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of its Elecsys® PRO-C3 test, a new diagnostic solution designed to assess the severity of liver fibrosis in patients showing signs of metabolic dysfunction–associated steatotic liver disease (MASLD). The test, developed in partnership with Nordic Bioscience, offers clinicians a simple and efficient method of iden...

Roche and Zealand Pharma in March struck a deal worth up to $5.3 billion to co-develop and co-commercialize amylin analog petrelintide as a potentially "next generation" weight loss drug. Executives at both firms told CNBC a "very competitive process" left both firms hashing out the details until the eleventh hour.

Tariff threats are fueling a new wave of U.S. manufacturing investments from the pharmaceutical industry.

Dublin, April 30, 2025 (GLOBE NEWSWIRE) -- The "Blood-Based Biomarker Market - A Global and Regional Analysis: Focus on Disease, Application, and Country-Level Analysis, 2025-2035" report has been added to ResearchAndMarkets.com's offering. The global blood-based biomarker market is poised for substantial growth, driven by the increasing demand for non-invasive diagnostic techniques and advance...

Basel, 30 April 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending an update to the European Union (EU) label for Phesgo®, a subcutaneous (SC) fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab), for human epidermal growth factor r...

Amid recession worries and tumbling markets; President Trump's tariffs are still helping the U.S. economy achieve key wins. Many huge corporations have announced plans to invest billions in U.S. manufacturing.

Roche's Q1 revenues beat Street consensus, but key growth products underperformed, making the beat less appealing. Mid-sized products like Phesgo, Xolair, and Polivy drove the revenue beat, compensating for the underperformance of larger products. The diagnostics division faced pricing headwinds in China, impacting overall performance, but other geographies helped offset the decline and resulte...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the New England Journal of Medicine (NEJM) has published a detailed analysis of the Phase III CENTERSTONE trial of Xofluza® (baloxavir marboxil). The trial met its primary endpoint, showing a single, oral dose of Xofluza taken by people infected with influenza r...